Login to Your Account



Other News To Note


Tuesday, July 26, 2011
NanoViricides Inc., of West Haven, Conn., said that its HIV candidate had equivalent efficacy to a highly active antiretroviral therapy triple drug cocktail in an animal study with no evidence of toxicity. The drug is designed to mimic the cellular structures that HIV uses to bind to cells, and has the potential to complement HAART therapy.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription